Evidence map›Paper›PMID 28678786›Full record

ArticlePLoS genetics2017

Bidirectional interplay of HSF1 degradation and UPR activation promotes tau hyperphosphorylation.

Eunhee Kim, Kazuko Sakata, Francesca-Fang Liao

Open access · goldAbstract read
In one paragraph

Article in PLoS genetics, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers.

0numbers the graph read from it
0cells of the map it votes in
35citing papers in PubMed
2.4field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

35 citing papers in PubMed, 52 citations in OpenAlex.

  1. Trial
  2. Article
  3. Review
  4. Review
  5. Article
  6. HSF1 Activation Mechanisms, Disease Roles, and Small Molecule Therapeutics.International journal of biological sciences · 2025
    Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Antioxidants (Basel, Switzerland) · 2023
    Article
  12. Review
  13. Review
  14. HSF1 and Its Role in Huntington's Disease Pathology.Advances in experimental medicine and biology · 2023
    Review
  15. Glia ofScience advances · 2022
    Article
  16. Article
  17. Review
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Eunhee KimDepartments of Pharmacology and Department of Anatomy and Neurobiology, TSRB 218A, University of Tennessee Health Science Center, Memphis, Tennessee, United States of America.
Kazuko SakataDepartments of Pharmacology and Department of Anatomy and Neurobiology, TSRB 218A, University of Tennessee Health Science Center, Memphis, Tennessee, United States of America.
Francesca-Fang LiaoDepartments of Pharmacology and Department of Anatomy and Neurobiology, TSRB 218A, University of Tennessee Health Science Center, Memphis, Tennessee, United States of America.
University of Tennessee Health Science Center · US

Funding

Is HSF1 the key in mediating Hsp90 inhibitor effect in AD?R01AG049772 · NIA · UNIVERSITY OF TENNESSEE HEALTH SCI CTR · PI LIAO, FRANCESCA-FANG · 2015 to 2019
$1.4M
Endothelial eNOS-deficient mice as chronic cerebral hypoperfusion modelR21NS091593 · NINDS · UNIVERSITY OF TENNESSEE HEALTH SCI CTR · PI DOPICO, ALEX M., LIAO, FRANCESCA-FANG · 2015 to 2016
$418k
NIA NIH HHS R01 AG049772NINDS NIH HHS R21 NS091593
6 · The paper itself

Abstract

The unfolded protein response (UPR) in the endoplasmic reticulum (ER) and the cytoplasmic heat stress response are two major stress response systems necessary for maintaining proteostasis for cellular health. Failure of either of these systems, such as in sustained UPR activation or in insufficient heat shock response activation, can lead to the development of neurodegeneration. Alleviation of ER stress and enhancement of heat shock response through heat shock factor 1 (HSF1) activation have previously been considered as attractive potential therapeutic targets for Alzheimer's disease (AD)-a prevalent and devastating tauopathy. Understanding the interplay of the two aforementioned systems and their cooperative role in AD remain elusive. Here we report studies in human brain and tau pathogenic mouse models (rTg4510, PS19, and rTg21221), identifying HSF1 degradation and UPR activation as precursors of aberrant tau pathogenesis. We demonstrate that chemical ER stress inducers caused autophagy-lysosomal HSF1 degradation, resulting in tau hyperphosphorylation in rat primary neurons. In addition, permanent HSF1 loss reversely causes chronic UPR activation, leading to aberrant tau phosphorylation and aggregation in the hippocampus of aged HSF1 heterozygous knock-out mice. The deleterious interplay of UPR activation and HSF1 loss is exacerbated in N2a cells stably overexpressing a pro-aggregation mutant TauRD ΔK280 (N2a-TauRD ΔK280). We provide evidence of how these two stress response systems are intrinsically interweaved by showing that the gene encoding C/EBP-homologous protein (CHOP) activation in the UPR apoptotic pathway facilitates HSF1 degradation, which likely further contributes to prolonged UPR via ER chaperone HSP70 a5 (BiP/GRP78) suppression. Upregulating HSF1 relieves the tau toxicity in N2a-TauRD ΔK280 by reducing CHOP and increasing HSP70 a5 (BiP/GRP78). Our work reveals how the bidirectional crosstalk between the two stress response systems promotes early tau pathology and identifies HSF1 being one likely key player in both systems.

Indexed as

Alzheimer DiseaseAnimalsAutophagyDNA-Binding ProteinsEndoplasmic Reticulum Chaperone BiPEndoplasmic Reticulum StressGene Expression RegulationHeat-Shock ProteinsHeat-Shock ResponseHeat Shock Transcription FactorsHippocampusHumansMiceMice, KnockoutNeuronsPhosphorylationDdit3 protein, mouseDNA-Binding ProteinsEndoplasmic Reticulum Chaperone BiPHeat-Shock ProteinsHeat Shock Transcription FactorsHsf1 protein, mouseHSPA5 protein, humanHspa5 protein, mousetau ProteinsTranscription Factor CHOPTranscription Factors

Identifiers

PMID28678786
PMCPMC5517072
OpenAlexW2727654194

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.